In the early ’60s, a soil sample collected in southern Italy yielded a bacterium, Streptomyces peucetius, that produced a red anthracycline compound. It became known first as daunomycin, later as daunorubicin, and within a decade was part of induction treatment for acute myeloid leukemia (AML). It still is, even as the disease has been reclassified around recurrent genetic alterations and targeted drugs.
Its role in hematology goes well beyond AML, but AML is where it’s most closely identified, as one of the two drugs behind 7+3, the regimen that has anchored intensive treatment for decades.
Compounds From Soil Bacteria
Long before large molecular libraries and structure-guided drug design, microorganisms were an unusually productive source of medicines. Bacteria live in chemically competitive environments, and many produce secondary metabolites capable of disrupting the growth or survival of neighboring organisms.
Antibiotics were the obvious yield, but microbial screening also turned up compounds capable of damaging malignant cells. Actinomycin D, mitomycin C, bleomycin and the anthracyclines all came from microorganisms or their derivatives. Many of these molecules interfere with DNA replication, transcription or integrity, properties that can be antimicrobial in one context and antitumor in another.
Streptomyces and related actinomycetes became one of the richest natural sources of anticancer compounds. Anthracyclines form an especially large chemical family, with more than 2,000 representatives described, though only a small fraction became medicines.
Where Daunorubicin Came From
In 1960, an Italian collaboration between Farmitalia and the Istituto Nazionale dei Tumori began studying a strain of S. peucetius isolated from soil collected near Castel del Monte in Apulia. The organism produced a red anthracycline with antitumor activity. Italian investigators called it daunomycin, closely related work in France produced rubidomycin. The compound eventually became known internationally as daunorubicin.
The discovery also showcases a general feature of natural-product drug development: the microorganism itself became a platform for finding related compounds. A mutated strain of S. peucetius subsequently produced 14-hydroxy-daunorubicin, better known as doxorubicin or Adriamycin. Doxorubicin developed a broader role across solid tumors and hematologic malignancies, while daunorubicin became particularly important in acute leukemia.
Later anthracyclines, including idarubicin and epirubicin, extended the family. Daunorubicin was not a synthetic molecule designed around a known leukemia target. Its clinical activity came first, understanding what it was doing to malignant cells followed.
How Daunorubicin Became Half of 7+3
Daunorubicin and cytarabine had independently demonstrated activity against acute leukemia. The problem was durability. Single-agent treatment and early combinations could produce remissions, but these were limited and frequently short-lived. The development was learning how to use the two drugs together.
In 70’s, Yates and colleagues reported a regimen combining seven days of continuous cytarabine with daunorubicin administered during the first three days. Complete remission was achieved in 63% of the reported patients with acute nonlymphocytic leukemia. The schedule became known as 7+3 and established an architecture for AML induction that has persisted for decades.
Cytogenetic risk groups, recurrent driver mutations, measurable residual disease and genomic classification have progressively divided AML into distinct subtypes, yet cytarabine plus an anthracycline remains the foundation of intensive induction for many patients. The persistence of 7+3 doesn’t mean AML treatment stood still. Outcomes have improved through better supportive care, consolidation, transplantation, dose optimization, salvage treatment and molecularly directed additions to induction.
You can also read about
What Makes Anthracyclines Effective?
Anthracyclines are often described as DNA-intercalating drugs, but it is only one component. Their planar ring structure can insert between DNA base pairs. In the case of daunorubicin, this interaction can also stabilize topoisomerase II–DNA cleavage complexes, preventing DNA religation and contributing to DNA damage during replication.
Anthracyclines can also alter chromatin and generate reactive oxygen species through their quinone structure, and contemporary work suggests their anticancer activity cannot be reduced to a single mechanism. That lack of molecular specificity creates toxicity, but it also gives them activity across genetically diverse leukemic populations.
The Price of Anthracycline Activity
The major concern with anthracyclines is cardiotoxicity. Anthracycline exposure can cause myocardial injury, cardiomyopathy and heart failure, with risk increasing with cumulative exposure, which places a ceiling.
Cardiotoxicity was explained largely through anthracycline redox cycling and generation of reactive oxygen species, but the model has become more detailed. Mammalian cells express two topoisomerase II isoforms. Topoisomerase IIα is strongly associated with proliferating cells, whereas topoisomerase IIβ is present in cardiomyocytes. Anthracycline interaction with topoisomerase IIβ can produce DNA damage and downstream mitochondrial dysfunction in the heart. Oxidative stress, iron handling and altered calcium homeostasis appear to interact.
This has created a specific drug-development goal: preserve the antitumor properties of anthracyclines while separating them from the mechanisms responsible for cardiac damage. Experimental analogues, altered drug-delivery systems and biosynthetic engineering are different approaches. Some newer work has even questioned whether DNA damage must remain inseparable from anthracycline efficacy, with compounds emphasizing chromatin damage showing antitumor activity with less cardiotoxicity in preclinical models.
Reinventing Daunorubicin Without Replacing It
CPX-351 took the same two agents, cytarabine and daunorubicin, and encapsulated them together in liposomes at a fixed 5:1 molar ratio. The formulation was designed to maintain a pharmacologically favorable drug ratio and alter drug exposure and delivery compared with administering them independently.
Progress in oncology doesn’t always require discarding old drugs, sometimes it comes from understanding their pharmacology well enough to use them differently. CPX-351 ultimately established a role in selected higher-risk AML populations, particularly therapy-related AML and AML with myelodysplasia-related features under the classifications used during its development. Subsequent changes in AML classification have made patient selection more nuanced.
Daunorubicin in Modern AML Treatment
Selecting treatment according to molecular biology is a relatively recent development. Daunorubicin entered leukemia treatment before anyone could target FLT3, IDH, BCL2 or menin. In 2026, the question of intensive induction versus venetoclax-based approaches is increasingly being considered even in populations historically viewed as candidates for intensive chemotherapy.
And can it be delivered with greater selectivity and less cardiac cost as the molecules and regimens around it continue to change? Genetic engineering of Streptomyces biosynthetic pathways, semisynthetic modification, altered sugar structures are different ways of modifying molecules that nature originally produced.
Determining which patients benefit enough from anthracycline-based therapy to justify its toxicity, and which patients can achieve better outcomes through a different therapeutic architecture, is becoming increasingly relevant.
You can also read about
